← Issue №13/ week of Sep 27, 2026/Hepatology

Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology review · Sep 21, 2026 · J Gastro Hep · IF 3.5

Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes.

New therapytranslationalguidelinecost-effectivenessviral hepatitis
Clinical takeawayConsider STRIDE regimen as frontline dual immunotherapy for HBV-predominant unresectable hepatocellular carcinoma, particularly in cirrhotic patients with portal hypertension, as it establishes a VEGF-free standard.
What it foundSTRIDE regimen (single-dose tremelimumab plus regular durvalumab) improved median overall survival to 25.26 vs. 14.09 months (compared to standard therapy) in HBV-predominant unresectable hepatocellular carcinoma.
ContextThis confirms and extends prior evidence supporting dual immunotherapy in HBV-predominant uHCC, establishing STRIDE as a VEGF-free standard in APASL guidelines.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Lau G · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues